Roth Capital Affirms BioBlast Pharma (ORPN) at 'Buy'; Sees Trehalose Plan Heading in Right Direction
-
BioBlast Pharma Announces Pricing of $6.7 Million Registered Direct Offering
-
Roth Believes BioBlast (ORPN) Management Made Prudent Decision with Cabaletta Phase 2b
-
Roth Capital Bullish on Recent BioBlast Pharma (ORPN) Hires; Reaffirms at 'Buy'
-
Roth Capital Positive on BioBlast Pharma (ORPN) Following Q2 Report; H215 Should be Busy with Phase 3 Initiations
-
Bio Blast Pharma (ORPN) PT Raised to $25 at Roth Capital
-
Roth Affirms BioBlast Pharma (ORPN) at 'Buy' Following Q1 Report; U.S. Phase II/III HOPEMD Enrollment Remains Next Milestone
-
BioBlast Pharma's (ORPN) Cabaletta Fast Track Designation Viewed as Incremental Positive by Roth Capital; 'Buy' Rating Affirmed
-
BioBlast Pharma to Present at the 27th Annual ROTH Investor Conference
-
Upcoming Milestones, Key Investment Points for Bio Blast Pharma (ORPN) Being Missed by Investors - Roth Capital
-
Roth Affirms Bio Blast Pharma (ORPN) at 'Buy'; Plenty of Catalysts Ahead in Next 12 - 18 Months
-
Roth Capital Positive on BioBlast Pharma (ORPN) CEO Appointment; Affirms at 'Buy'
-
UPDATE: Roth Capital Starts Bio Blast Pharma (ORPN) at Buy
-
Bio Blast Pharma (ORPN) IPO Opens, Trades Lower

